Syncona eyes a matching pair

Why Syncona felt two gene therapy investments would fare better as one company

Ten months after rounding out its gene therapy strategy with the last two investments in a five-company portfolio, Syncona has decided that two of its companies will fare better as a single entity.

Syncona Ltd. (LSE:SYNC) has decided to merge Gyroscope Therapeutics Ltd. with Orbit Biomedical Ltd., which it says creates the first gene therapy company for retinal diseases that includes a

Read the full 619 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE